155 related articles for article (PubMed ID: 21499123)
1. Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
Ziefle S; Egberts F; Heinze S; Volkenandt M; Schmid-Wendtner M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Heinz A; Hauschild A; Schaefer M
J Immunother; 2011 May; 34(4):403-8. PubMed ID: 21499123
[TBL] [Abstract][Full Text] [Related]
2. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
3. Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
Brandberg Y; Johansson H; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J;
Acta Oncol; 2013 Aug; 52(6):1086-93. PubMed ID: 23621752
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life, fatigue, and depression under low-dose IFN-α therapy in melanoma patients.
Reuter K; Albrecht K; Seelig H; Meiss F; Mauch C; Kreuzberg N; Nashan D
J Immunother; 2014; 37(9):461-7. PubMed ID: 25304729
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.
Dixon S; Walters SJ; Turner L; Hancock BW
Br J Cancer; 2006 Feb; 94(4):492-8. PubMed ID: 16449995
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women.
Browall M; Ahlberg K; Karlsson P; Danielson E; Persson LO; Gaston-Johansson F
Eur J Oncol Nurs; 2008 Jul; 12(3):180-9. PubMed ID: 18343197
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
10. Impact of cancer-related symptom synergisms on health-related quality of life and performance status.
Ferreira KA; Kimura M; Teixeira MJ; Mendoza TR; da Nóbrega JC; Graziani SR; Takagaki TY
J Pain Symptom Manage; 2008 Jun; 35(6):604-16. PubMed ID: 18362059
[TBL] [Abstract][Full Text] [Related]
11. Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression.
Albrecht K; Droll H; Giesler JM; Nashan D; Meiss F; Reuter K
Psychooncology; 2013 Sep; 22(9):1972-8. PubMed ID: 23288588
[TBL] [Abstract][Full Text] [Related]
12. Chronic non-malignant pain patients report as poor health-related quality of life as palliative cancer patients.
Fredheim OM; Kaasa S; Fayers P; Saltnes T; Jordhøy M; Borchgrevink PC
Acta Anaesthesiol Scand; 2008 Jan; 52(1):143-8. PubMed ID: 18005378
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study.
Arndt V; Merx H; Stegmaier C; Ziegler H; Brenner H
J Clin Oncol; 2004 Dec; 22(23):4829-36. PubMed ID: 15570086
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of health related quality of life for pediatric patients with ureteropelvic junction obstruction.
Parekh AD; Thomas JC; Trusler L; Ankerst DP; Deshpande JK; Adams MC; Pope JC; Brock JW
J Urol; 2008 Nov; 180(5):2171-5; discussion 2175-6. PubMed ID: 18804796
[TBL] [Abstract][Full Text] [Related]
15. Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy.
Ozturk A; Sarihan S; Ercan I; Karadag M
Am J Clin Oncol; 2009 Feb; 32(1):65-72. PubMed ID: 19194128
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study.
Robinson DW; Cormier JN; Zhao N; Uhlar CM; Revicki DA; Cella D
Melanoma Res; 2012 Feb; 22(1):54-62. PubMed ID: 22027908
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
18. The effects of testicular cancer treatment on health-related quality of life.
Vidrine DJ; Hoekstra-Weebers JE; Hoekstra HJ; Tuinman MA; Marani S; Gritz ER
Urology; 2010 Mar; 75(3):636-41. PubMed ID: 19963242
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data.
Bordeleau L; Szalai JP; Ennis M; Leszcz M; Speca M; Sela R; Doll R; Chochinov HM; Navarro M; Arnold A; Pritchard KI; Bezjak A; Llewellyn-Thomas HA; Sawka CA; Goodwin PJ
J Clin Oncol; 2003 May; 21(10):1944-51. PubMed ID: 12743147
[TBL] [Abstract][Full Text] [Related]
20. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
